Abstract
Bone marrow failure is associated with high morbidity and mortality after hematopoietic stem cell transplantation (HSCT) due to complications associated with prolonged neutropenia. Using the positron emission tomography (PET) imaging probe, 3’-deoxy-3 18F-fluorothymidine (18FLT), we illustrate HSC homing very early after myeloablative HSCT in adults in vivo. In our prospective trial, NCT01338987, we imaged 14 patients undergoing myeloablative transplantation with Cytoxan and total body irradiation and evaluated corresponding uptake of radiotracer 18FLT in osseous structures throughout the bone marrow compartment following full myeloblation, early engraftment, and hematopoietic reconstitution. 18FLT was safe and did not delay engraftment. Objective increases in 18FLT uptake measured by standardized uptake value (SUV) revealed evidence of stem cell homing to medullary bone marrow sites within 5 days of donor cell infusion. In patients without relapse (n=11), mean thoracic spine SUV was greater among patients with rapid (<21 days) as compared to slow engraftment (≥21 days). Using SUV, we could differentiate full ablation (SUV of 0.65) from early engraftment at day +5-6 (SUV 1.1, p <0.05). 18FLTsignal increases revealed a consistent pattern of marrow recovery that recapitulated fetal ontogeny, claiming sites of hematopoiesis that are normally dormant in adults. These findings were substantiated with in vitro cellular recovery data. 18FLT SUV could also predict marrow recovery after secondary graft failure without additional HSC infusion. In summary, our data show that 18FLT reveals homing, kinetics, and biology of hematopoietic engraftment in adults in vivo.18FLT could predict engraftment very early after HSCT and could be of value to predict primary or secondary graft failure in high risk populations, such as recipients of cord blood transplantation or haplo-identical transplantation.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
![](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/124/21/10.1182_blood.v124.21.1147.1147/3/m_inf01.gif?Expires=1726889945&Signature=vEiR5z6JTLuEKLWgQ8uHfyIrVopuKerGMiXiB6l37CcK8a~KIlVT-FlaUDQqOpq9nlKBtf-lPYqPZrGtcAskzIzMenamrp4ItOsJ4ZBRTRkLpX8EawaGmaQCm7ay7ygxlOjVQH3ILNU71Uv~SfFuVRfrW7N6uMBzZI8DkD43Vt5-kjLOqp2OHgbSrxYPH3Xn3dlca76gMnJmgo86x5REa~-cKXrjNs4hq2mwndw283Plvji~HVlliFh01-YdP5MItymKgkcCO0ybvKNibeweAEMHmDwI51B9GdYraeroYwJVyU4ycmTnJZpL9SRfuGj3x79JQbJxEggwp0R6I4g63A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This icon denotes a clinically relevant abstract
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal